Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients
New England Journal of Medicine · 23.04.2026 · 394 (16) · 1583-1594
DOI: 10.1056/nejmoa2502457 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 23.04.2026. Verfasst von Christopher C Butler und 42 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, COVID-19 Drug Treatment, Ritonavir. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Department of Health, Canadian Institutes of Health Research, National Institute for Health and Care Research.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
- Upstream Lab, MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto.
- Department of Family and Community Medicine, St. Michael's Hospital, Toronto.
- Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto.
- Dalla Lana School of Public Health, University of Toronto, Toronto.
- Respiratory Trials Unit, Nuffield, Department of Medicine, University of Oxford, Oxford, United Kingdom.
ORCID-Profile: Christopher C Butler, Jienchi Dorward, Peter Selby, Todd C Lee, Michelle A Detry, Christina T Saunders
Förderung
- Department of Health
- Canadian Institutes of Health Research
- National Institute for Health and Care Research
Zitieren
APA
Butler, C. C., Pinto, A. D., Harris, V., Holmes, J., Rahman, N. M., Cureton, L., Hayward, G., Richards, D. B., Lowe, D. M., Standing, J. F., Breuer, J., Hood, K., Png, M. E., Petrou, S., Dorward, J., Patel, M. G., Thomas, N. P. B., Evans, P., Hart, N. D., …, & PANORAMIC Trial and CanTreatCOVID Trial Collaborative Groups (2026). Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients. New England Journal of Medicine, 394(16), 1583-1594. https://doi.org/10.1056/nejmoa2502457
Vancouver
Butler CC, Pinto AD, Harris V, Holmes J, Rahman NM, Cureton L, et al. Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients. New England Journal of Medicine. 2026;394(16):1583-1594. doi:10.1056/nejmoa2502457
BibTeX
@article{Butler2026,
author = {Butler, Christopher C and Pinto, Andrew D and Harris, Victoria and Holmes, Jane and Rahman, Najib M and Cureton, Lucy and Hayward, Gail and Richards, Duncan B and Lowe, David M and Standing, Joseph F and Breuer, Judith and Hood, Kerenza and Png, May Ee and Petrou, Stavros and Dorward, Jienchi and Patel, Mahendra G and Thomas, Nicholas P B and Evans, Philip and Hart, Nigel D and Jani, Bhautesh D and Hosseini, Banafshe and Murthy, Srinivas and McBrien, Kerry and Condon, Amanda and McDonald, Emily G and Daley, Peter and Greiver, Michelle and da Costa, Bruno R and Selby, Peter and Jüni, Peter and Lee, Todd C and Shi, Haolun and Detry, Michelle A and Saunders, Christina T and Fitzgerald, Mark and Berry, Nicholas S and Saville, Benjamin R and Khoo, Saye H and Nguyen-Van-Tam, Jonathan S and Hobbs, F D Richard and Yu, Ly-Mee and Little, Paul and PANORAMIC Trial and CanTreatCOVID Trial Collaborative Groups, PANORAMIC Trial and CanTreatCOVID Trial Collaborative Groups},
title = {Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {16},
pages = {1583--1594},
doi = {10.1056/nejmoa2502457}
}
EUVIMED